These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 33797786)

  • 1. Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Nijhuis FAP; Esselink R; de Bie RMA; Groenewoud H; Bloem BR; Post B; Meinders MJ
    Mov Disord; 2021 Jun; 36(6):1293-1307. PubMed ID: 33797786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Tsunemi T; Oyama G; Saiki S; Hatano T; Fukae J; Shimo Y; Hattori N
    Mov Disord; 2021 Aug; 36(8):1759-1771. PubMed ID: 33899262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
    Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
    Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
    J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
    Thaler A; Barer Y; Gross R; Cohen R; Bergmann L; Jalundhwala YJ; Giladi N; Chodick G; Shalev V; Gurevich T
    Adv Ther; 2022 May; 39(5):2009-2024. PubMed ID: 35247187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
    Antonini A; Pahwa R; Odin P; Isaacson SH; Merola A; Wang L; Kandukuri PL; Alobaidi A; Yan CH; Bao Y; Zadikoff C; Parra JC; Bergmann L; Chaudhuri KR
    CNS Drugs; 2022 Dec; 36(12):1269-1283. PubMed ID: 36414908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Fernandez HH; Boyd JT; Fung VSC; Lew MF; Rodriguez RL; Slevin JT; Standaert DG; Zadikoff C; Vanagunas AD; Chatamra K; Eaton S; Facheris MF; Hall C; Robieson WZ; Benesh J; Espay AJ
    Mov Disord; 2018 Jul; 33(6):928-936. PubMed ID: 29570853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Device-aided therapies for advanced Parkinson disease: insights from an international survey.
    Marsili L; Bologna M; Miyasaki JM; Colosimo C
    Neurol Sci; 2021 Jul; 42(7):2961-2964. PubMed ID: 33550525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
    Deuschl G; Antonini A; Costa J; Śmiłowska K; Berg D; Corvol JC; Fabbrini G; Ferreira J; Foltynie T; Mir P; Schrag A; Seppi K; Taba P; Ruzicka E; Selikhova M; Henschke N; Villanueva G; Moro E
    Mov Disord; 2022 Jul; 37(7):1360-1374. PubMed ID: 35791767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selection of the optimal device-aided therapy in Parkinson's disease].
    Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
    Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.